Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Tsai, C
Chiu, C
Chou, T
Li, L
Chang, K
Chen, Y
Tsai, S
Perng, R
机构：
[1] Taipei Vet Gen Hosp, Chest Dept, Taipei, Taiwan
[2] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80492-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [1] Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
    Chou, TY
    Chiu, CH
    Li, LH
    Hsiao, CY
    Tzen, CY
    Chang, KT
    Chen, YM
    Perng, RP
    Tsai, SF
    Tsai, CM
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (10) : 3750 - 3757
  • [2] Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Tsai, CM
    Chiu, CH
    Chou, TY
    Li, LH
    Hsiao, CY
    Chen, M
    Perng, RP
    Tsai, SF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 641S - 641S
  • [3] 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
    Pao, W
    Miller, VA
    Kris, MG
    [J]. SEMINARS IN CANCER BIOLOGY, 2004, 14 (01) : 33 - 40
  • [4] Epidermal Growth Factor Receptor (EGFR) mutation testing in non-small cell lung cancer (NSCLC) patients
    Eaton, Helen
    Dutton, L.
    Wallace, A. J.
    Howard, E.
    Gaunt, L.
    Blackhall, F.
    Newman, W.
    [J]. JOURNAL OF MEDICAL GENETICS, 2011, 48 : S72 - S72
  • [5] Epidermal Growth Factor Receptor (EGFR) Mutation Testing in non-small cell lung cancer (NSCLC) patients
    Wallace, Andrew
    Howard, E.
    Dutton, L.
    Elles, R. G.
    Newman, W.
    [J]. JOURNAL OF MEDICAL GENETICS, 2010, 47 : S66 - S66
  • [6] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS (TKIS) ERLOTINIB AND GEFITINIB IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC)
    Naskhletashvili, D. R.
    Gorbounova, V.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 435 - 435
  • [7] Epidermal growth factor receptor (EGFR) mutation testingin non-small cell lung cancer (NSCLC) patients (pts).
    Sequist, L. V.
    Joshi, V. A.
    Jänne, P. A.
    Fidias, P.
    Muzikansky, A.
    Meyerson, M.
    Haber, D. A.
    Kucherlapati, R.
    Johnson, B. E.
    Lynch, T. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 408S - 408S
  • [8] The quantification of epidermal growth factor receptor (EGFR) in plasma is a prognostic factor in advanced non-small cell lung cancer (NSCLC) patients
    Camps, C.
    Sirera, R.
    Munoz-Navarro, M.
    Lopez-Vivanco, G.
    Alonso, G.
    Provencio, M.
    Gonzalez-Larriba, J.
    de las Penas, R.
    Taron, M.
    Rosell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors
    Karachaliou, Niki
    Rosell, Rafael
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (03) : 114 - 117
  • [10] Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer
    Mu, XL
    Li, LY
    Zhang, XT
    Wang, MZ
    Feng, RE
    Cui, QC
    Zhou, HS
    Guo, BQ
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (12) : 4289 - 4294
12345